semaglutide
Stop Letting FDA Exclusion Hit Semaglutide Pharmacies
Pharmacies must replace 503B bulk sources with FDA-approved pre-qualified suppliers and consider in-house sterile compounding to keep semaglutide on the shelves. The FDA’s recent move to exclude semaglutide, tirzepatide and liraglutide from the 503B bulk list forces a rapid shift in supply-chain strategy. I’ve seen clinics scramble to